Skip to main content

Osteomyelitis

6
Pipeline Programs
7
Companies
9
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
1
2
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

AbbVie
DALVANCEApproved
dalbavancin
AbbVie
intravenous2014
14M Part D

Competitive Landscape

7 companies ranked by most advanced pipeline stage

AbbVie
AbbVieNORTH CHICAGO, IL
3 programs
2
1
1
DalbavancinPhase 31 trial
DalbavancinPhase 21 trial
DalbavancinPhase 21 trial
Active Trials
NCT03091439Terminated1Est. Aug 2017
NCT02685033Completed80Est. Dec 2017
NCT02344511Withdrawn0Est. Apr 2019
Innovation Pharmaceuticals
1 program
1
Oral co-amoxiclav or oral dicloxacillin onlyPhase 41 trial
Active Trials
NCT04563325Completed180Est. Aug 2024
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
1
CefadroxilPhase 11 trial
Active Trials
NCT03802552Completed17Est. Apr 2021
Pfizer
PfizerNEW YORK, NY
1 program
AntimicrobialN/A1 trial
Active Trials
NCT03559530Completed262Est. Dec 2019
Bonesupport
BonesupportGermany - Frankfurt
1 program
CERAMENT GN/A1 trial
Active Trials
NCT06555848Recruiting128Est. Oct 2032
Utah Medical
Utah MedicalIreland - Dublin
1 program
Peripherally Inserted Central CatheterN/A1 trial
Active Trials
NCT02311452Completed15,000
Biocomposites
BiocompositesChina - Shanghai
1 program
genex with gentamicinN/A1 trial
Active Trials
NCT07270380Not Yet Recruiting139Est. Oct 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Innovation PharmaceuticalsOral co-amoxiclav or oral dicloxacillin only
AbbVieDalbavancin
AbbVieDalbavancin
AbbVieDalbavancin
Colorado TherapeuticsCefadroxil
Biocompositesgenex with gentamicin
BonesupportCERAMENT G
PfizerAntimicrobial
Utah MedicalPeripherally Inserted Central Catheter

Clinical Trials (9)

Total enrollment: 15,807 patients across 9 trials

NCT04563325Innovation PharmaceuticalsOral co-amoxiclav or oral dicloxacillin only

Oral-only Antibiotics for Bone and Joint Infections in Children

Start: Sep 2020Est. completion: Aug 2024180 patients
Phase 4Completed
NCT02344511AbbVieDalbavancin

Dalbavancin vs Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis

Start: Mar 2016Est. completion: Apr 20190
Phase 3Withdrawn
NCT03091439AbbVieDalbavancin

Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis

Start: May 2017Est. completion: Aug 20171 patients
Phase 2Terminated
NCT02685033AbbVieDalbavancin

Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With Osteomyelitis

Start: Mar 2016Est. completion: Dec 201780 patients
Phase 2Completed
NCT03802552Colorado TherapeuticsCefadroxil

Cefadroxil and Cephalexin Drug Levels and Dosing in Pediatric Musculoskeletal Infections

Start: May 2019Est. completion: Apr 202117 patients
Phase 1Completed
NCT07270380Biocompositesgenex with gentamicin

Antibiotic Device for Osteomyelitis of the Extremities Pivotal Trial - Genex With Gentamicin.

Start: Apr 2026Est. completion: Oct 2028139 patients
N/ANot Yet Recruiting
NCT06555848BonesupportCERAMENT G

CERAMENT G as Part of the Surgical Treatment of Osteomyelitis in a Single-Stage Procedure

Start: Jun 2025Est. completion: Oct 2032128 patients
N/ARecruiting
NCT03559530PfizerAntimicrobial

Acinetobacter Baumannii-related Osteomyelitis: Clinical and Epidemiological Characterization

Start: May 2017Est. completion: Dec 2019262 patients
N/ACompleted
NCT02311452Utah MedicalPeripherally Inserted Central Catheter

Comparative Effectiveness of Intravenous v. Oral Antibiotic Therapy for Serious Bacterial Infections

Start: Jan 200915,000 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 15,807 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.